In December 2011, Tekturna® manufacturer Novartis announced its decision to terminate the clinical ALTITUDE study of the blood pressure drug based on the recommendation of the independent Data Monitoring Committee (DMC) overseeing the clinical trial study. Generically known as Aliskiren and as Rasilez® in the United Kingdom, Tekturna is an oral drug that was FDA-approved in March 2007 to treat high blood pressure (hypertension).
In the study, Type- 2 diabetics treated with Tekturna were found to be more likely to suffer non-fatal stroke, kidney injury, high potassium and low blood pressure than patients with Type-2 diabetes not treated with the drug.
Potentially dangerous side effects of Tekturna may include:
· Increased blood potassium levels (hyperkalemia)
· Kidney (renal) damage
· Low blood pressure (hypotension)
According to the Novartis announcement, the company “is recommending that ALTITUDE investigators remove Rasilez/Tekturna-based products from their patients’ treatment regimen and review their high blood pressure medication. Novartis is also reviewing the findings with DMCs of other clinical studies involving Rasilez/Tekturna-based products and combination therapies.”
Learn more at the Rasilez/Tekturna information center.
Read the Tekturna drug warning.
We are reviewing potential Tekturna lawsuits. If you or someone you love has experienced Tekturna side effects involving serious bleeding complications, please contact Jon L. Gelman via email or by calling 1.973.696.7900.